Department of Pathology, College of Basic Medical Sciences, Binzhou Medical University, Yantai, 264003, Shandong, China.
Department of Pathology, Yantai Yuhuangding Hospital, 20 Yudong Road Zhifu District, Yantai, 264000, Shandong, China.
Med Mol Morphol. 2024 Dec;57(4):320-325. doi: 10.1007/s00795-024-00398-9. Epub 2024 Jul 16.
Classical Hodgkin Lymphoma (CHL) is a rare malignant neoplasm of the lymphatic system. While CHL typically responds well to conventional treatments, some cases may experience relapse to other subtypes, with the development of secondary peripheral T-cell lymphoma (PTCL) being relatively uncommon. Herein, we report a rare case of nodal T follicular helper cell lymphomas,nos (nTFHL-NOS) secondary to CHL, accompanied by aberrant CD20 expression and clonal rearrangements of T-cell receptor (TCR) and immunoglobulin (IG). A 74-year-old male, was diagnosed with CHL, leaning toward the mixed cell type, 6 years ago. He received six cycles of the Adriamycin, Bleomycin, Vinblastine, Dacarbazine (ABVD) regimen, achieving complete clinical remission. The patient was admitted to our hospital due to the appearance of multiple skin nodules 66 months later. Histopathological analysis revealed nTFHL-NOS, with aberrant CD20 expression and clonal rearrangements of TCR and IG. The patient underwent two cycles of chemotherapy with brentuximab vedotin and the Gemcitabine-Oxaliplatin (G-mox) regimen, resulting in a reduction of the skin lesions to 2 cm × 1 cm. We discuss this rare case and review related literature.
经典型霍奇金淋巴瘤(CHL)是一种罕见的淋巴系统恶性肿瘤。虽然 CHL 通常对常规治疗反应良好,但有些病例可能会复发为其他亚型,继发性外周 T 细胞淋巴瘤(PTCL)的发展相对少见。在此,我们报告一例罕见的继发于 CHL 的结内滤泡辅助 T 细胞淋巴瘤,NOS(nTFHL-NOS),伴有异常的 CD20 表达和 T 细胞受体(TCR)和免疫球蛋白(IG)的克隆重排。一名 74 岁男性,6 年前被诊断为 CHL,倾向于混合细胞型。他接受了六个周期的阿霉素、博来霉素、长春花碱、达卡巴嗪(ABVD)方案治疗,达到完全临床缓解。66 个月后,该患者因出现多个皮肤结节而入院。组织病理学分析显示为 nTFHL-NOS,伴有异常的 CD20 表达和 TCR 和 IG 的克隆重排。患者接受了两个周期的 Brentuximab vedotin 和吉西他滨-奥沙利铂(G-mox)方案化疗,皮肤病变缩小至 2cm×1cm。我们讨论了这例罕见病例并复习了相关文献。